A comparative review of topical therapies for inflammatory bowel disease

Clinical Immunotherapeutics

Volumn 6, Issue 2, 1996, Pages 117-129

  Shah, Samir A ^a   Peppercorn, Mark A ^a  

^a BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOSALICYLIC ACID; BISMUTH DERIVATIVE; CORTICOSTEROID; CROMOGLYCATE DISODIUM; CYCLOSPORIN; INTERLEUKIN 10; LIDOCAINE; MESALAZINE; METRONIDAZOLE; SALAZOSULFAPYRIDINE; SHORT CHAIN FATTY ACID; SUCRALFATE;

COLITIS; COLON LAVAGE; ENTERITIS; PATIENT COMPLIANCE; PRIORITY JOURNAL; PROCTITIS; REVIEW; TOPICAL DRUG ADMINISTRATION; TOPICAL TREATMENT;

EID: 0029833837     PISSN: 11727039     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF03259508     Document Type: Review

References (105)

1. Podolsky DK. Inflammatory bowel disease. N Engl J Med 1991: 325:928-37, 1008-16
2. Peppercorn MA. Advances in drug therapy for inflammatory bowel disease. Ann Intern Med 1990; 112: 50-60
3. Geier DL, Miner PB. New therapeutic agents in the treatment of inflammatory bowel disease. Am J Med 1992; 93: 199-208
4. Hanauer SB. Inflammatory bowel disease. N Engl J Med 1996; 334: 841-8
5. Allgayer H. Sulfasalazine and 5-ASA compounds. Gastroenterol Clin North Am 1992; 21: 643-58
6. Miner PB, Peppercorn MA, Targan SR. A rational approach to 5-aminosalicylic acid therapy in ulcerative colitis. Hosp Pract 1993;28:1S-24S
7. Sutherland LR. Topical treatment of ulcerative colitis. Med Clin North Am 1990:74: 119-31
8. Truelove SC. Treatment of ulcerative colitis with local hydrocortisone. BMJ 1956; 2: 1267
9. Azad Khan AK, Piris J. Truelove SC. An experiment to determine the active therapeutic moiety of sulphasalazine. Lancet 1977; 11:892-5
10. Van Hees PAM, Bakker JH, Van Tongeren JHM. Effect of sulphapyridine, 5-aminosalicylic acid and placebo in patients with idiopathic proctitis: a study to determine the active therapeutic moiety of sulphasalazine. Gut 1980; 21: 632-5
11. Fruhmorgen P, Demling L. On the efficacy of ready-made-up commercially available salicylazosulphapyridine enemas in the treatment of proctitis. proctosigmoiditis and ulcerative colitis involving rectum, sigmoid and descending colon. Hepatogastroenterology 1980; 27: 473-6
12. Palmer KR, Goepel JR, Holdsworth CD. Sulphasalazine retention enemas in ulcerative colitis: a double-blind trial. BMJ 1981; 282: 1571-3
13. Peskar BM, Dreyling KW. May B, et al. Possible mode of action of 5-aminosalicylic acid. Dig Dis Sei 1987; 32: 5 IS 56S
14. Lauritsen K. Laursen LS, Bukhave K, et al. Effects of topical 5-aminosalicylic acid and prednisolone on prostaglandin E? and leukotriene B4 levels determined by equilibrium in vivo dialysis of rectum in relapsing ulcerative colitis. Gastroenterology 1986:91:837-44
15. Ahnfelt-Ronne I, Nielsen OH, Christensen A, et al. Clinical evidence supporting the radical scavenger mechanism of 5aminosalicylic acid. Gastroenterology 1990; 98: 1162-9
16. MacDermott RP, Schloemann SR, Bertovich MJ. et al. Inhibi lion of antibody secretion by 5-aminosalicylic acid. Gastroenterology 1989:96:442-8
17. Greenfield SM. Punchard NA. Teare JP, et al. The mode of action of the aminosalicylates in inflammatory bowel disease. Aliment Pharmacol The'r 1993; 7: 369-83
18. Campieri M, Corbelli C, Gionchetti P. et al. Spread and distribution of 5-ASA colonie foam and 5-ASA enema in patients with ulcerative colitis. Dig Dis Sei 1992: 37: 1890-7
19. Chapman NJ. Brown ML, Phillips SF. et al. Distribution of mesalamine enemas in patients with active distal ulcerative colitis. Mayo Clin Proc 1992; 67: 245-8
20. Vitti RA, Meyers F, Knight LC. et al. Quantitative distribution of radiolabeled 5-aminosalicylic acid enemas in patients with left-sided ulcerative colitis. Dig Dis Sei 1989; 34: 1792-7
21. Campieri M, Lanfranchi GA, Boschi S, et al. Topical administration of 5-aminosalicylic acid enemas in patients with ulcerative colitis. Studies on rectal absorption and excretion. Gut 1985:26:400-5
22. Sutherland LR, Martin F, Grer S. et al. 5-Aminosalicylic acid enema in the treatment of distal ulcerative colitis, procto sigmoiditis, and proctitis. Gastroenterology 1987:92: 1894-8
23. Campieri M, Gionchetti P, Belluzzi A, et al. Optimum dosage of 5-aminosalicylic acid as rectal enemas in patients with active ulcerative colitis. Gut 1991: 32: 929-31
24. Isaacs KL, Murphy D. Pancreatitis after rectal administration of 5-aminosalicylic acid. J Clin Gastroenterol 1990; 12(2): 198-9
25. Barber GB, Lee DE. Antonioli DA. et al. Refractory distal ulcerative colitis responsive to 5-aminosalicylate enemas. Am J Gastroenterol 1985: 80: 612-4
26. Hanauer SB, Schultz PA. Efficacy of 5-ASA enemas for steroid dependent ulcerative colitis [abstract). Gastroenterology 1986:90: 1449
27. Friedman LS, Richter JM, Kirkham SE. et al. 5-aminosalicylic acid enemas in refractory distal ulcerative colitis: a randomized, controlled trial. Am J Gastroenterology 1986; 81: 412-8
28. Guarino J, Chatzinoff M, Berk T, et al. 5-Aminosalicylic acid enemas in refractory distal ulcerative colitis: long-term results. Am J Gastroenterology 1987; 82: 732-7
29. McPhee MS, Swan JT, Biddle WL. et al. Proctocolitis unresponsive to conventional therapy. Response to 5-aminosalicylic acid enemas. Dig Dis Sei 1987; 32: 76S-81S
30. Biddle WL, Miner PB. Long-term use of mesalamine enemas to induce remission in ulcerative colitis. Gastroenterology 1990: 99: 113-8
31. Campieri M. Paoluzi P, D'Albasio G, et al. Better quality of therapy with 5-ASA colonie foam in active ulcerative colitis. A multicenter comparative trial with 5-ASA enema. Die Dis Sei 1993:38: 1843-50
32. Ginsberg AL. Topical salicylate therapy (4-ASA and 5 ASA enemas). Gastroenterol Clin North Am 1989; 18: 35-42
33. Biddle WL, Greenberger NJ, Swan JT, et al. 5-Aminosalicylic acid enemas: effective agent in maintaining remission in left-sided ulcerative colitis. Gastroenterology 1988:94: 1075 9
34. Miner P, Daly R, Nesto T. et al. The effect of varying dose intervals of mesalamine enemas for the prevention of relapse in distal ulcerative colitis (abstract). Gastroenterology 1994; 106:A736
35. Kam L, Cohen H, Dooley C, et al. A double-blind comparison of mesalamine rectal suspension enema and oral sulfasalazine in the treatment of distal ulcerative colitis [abstract]. Gastroenterology 1994; 106: A707
36. Mantzaris GJ, Hatzis A, Petraki K, et al. Intermittent therapy with high-dose 5-aminosalicylic acid enemas maintains remission in ulcerative proctitis and proctosigmoiditis. Dis Colon Rectum 1994; 37: 58-62
37. D'Albasio G, Trallori G, Ghetti A. Intermittent therapy with high-dose 5-aminosalicylic acid enemas for maintaining remission in ulcerative proctosigmoiditis. Dis Colon Rectum 1990:33:394-7
38. Campieri M, De Franchis R, Blanchi Porro G, et al. Mesalazine (5-aminosalicylic acid) suppositories in the treatment of ulcerative proctitis or distal proctosigmoiditis. A randomized controlled trial. Seand J Gastroenterol 1990; 25: 663-8
39. Ngo Y, Gelinet JM, Ivanovic A, et al. Efficacy of a daily application of mesalamine (Pentasa) suppository with progressive release, in the treatment of ulcerative proctitis: a double-blind versus placebo randomized trial. Gastroenterol Clin Biol 1992; 16: 782-6
40. Williams CN, Haber G, Aquino JA. Double-blind, placebocontrolled evaluation of 5-ASA suppositories in active distal proctitis and measurement of extent of spread using 99nTTclabelled 5-ASA suppositories. Dig Dis Sei 1987; 32: 71S-75S
41. Campieri M, Gionchetti P, Belluzzi A, et al. 5-Aminosalicylic acid suppositories in the management of ulcerative colitis. Dis Colon Rectum 1989; 32: 398-9
42. Campieri M, Gionchetti P, Belluzzi A, et al. 5-Aminosalicylic acid enemas or suppositories in distal ulcerative colitis. J Clin Gastroenterol 1988; 10:406-9
43. Hanauer S, Borgen L, Reiss L. Maintenance treatment of ulcerative proctitis with mesalamine suppositories: results of a multicenter two year controlled trial [abstract]. Gastroenterology 1992; 104: A634
44. Ginsberg AL, Beck LS, Mclntosh TM, et al. Treatment of leftsided ulcerative colitis with 4-aminosalicylic acid enemas. A double-blind, placebo-controlled trial. Ann Intern Med 1988; 108: 195-9
45. Gandolfo J, Farthing M, Powers G, et al. 4-Aminosalicylic acid retention enemas in treatment of distal colitis. Dig Dis Sei 1987; 32: 700-4
46. Campieri M, Lanfranchi GA, Bertoni F, et al. A double-blind clinical trial to compare the effects of 4-aminosalicylic acid to 5-aminosalicylic acid in topical treatment of ulcerative colitis. Digestion 1984; 29: 231-4
47. Selby WS, Bennet MK, Jewell DP. Topical treatment of distal ulcerative colitis with 4-amino-salicylic acid enemas. Digestion 1984; 29: 231-4
48. Sharma MP, Duphare HV. Dasarathy S. A prospective randomized double blind trial comparing prednisolone and 4aminosalicylic acid enemas in acute distal ulcerative colitis. J Gastroenterol Hepatol 1992; 7: 173-7
49. Nagy F, Karacsony G, Varro V. Experience with topical administration of 4-aminosalicylic acid in ulcerative colitis. Dis Colon Rectum 1989; 32: 134-7
50. Hanauer SB. Inflammatory bowel disease revisited: newer drugs. Scand J Gastroenterol 1990; 25 Suppl. 175: 97-106
51. Hanauer SB, Meyers S, Sachar DB. The pharmacology of antiinflammatory drugs in inflammatory bowel disease. In: Kirsner JB, Shorter RG, editors. Inflammatory bowel disease. 4th ed. Baltimore: Williams & Wilkins, 1995: 643-63
52. Boumpas DT, Chrousos GP, Wilder RL, et al. Glucocorticoid therapy for immune-mediated diseases: basic and clinical correlates. Ann Intern Med 1993;119: 1198-208
53. Truelove SC. Treatment of ulcerative colitis with local hydrocortisone hemisuccinate sodium: a report on a controlled therapeutic trial. BMJ 1958; 1: 1437
54. Watkinson G. Treatment of ulcerative colitis with topical hydrocortisone hemisuccinate sodium: a controlled trial employing restricted sequential analysis. BMJ 1958; 2: 1077
55. Jewell DP. Corticosteroids for the management of ulcerative colitis and Crohn's disease. Gastroenterol Clin North Am 1989; 18:21-33
56. Somerville KW, Langman MJS, Kane SP, et al. Effect of treatment on symptoms and quality of life in patients with ulcerative colitis: comparative trial of hydrocortisone acetate foam and prednisolone 21-phosphate enemas. BMJ 1985; 291: 866
57. Ruddell WSJ, Dickinson RJ, Dixon MF, et al. Treatment of distal ulcerative colitis (proctosigmoiditis) in relapse: comparison of hydrocortisone enemas and rectal hydrocortisone foam. Gut 1980; 21: 885-9
58. Lennard-Jones JE, Baron JH, Connell AM, et al. A doubleblind controlled trial of prednisolone-21-phosphate suppositories in the treatment of idiopathic proctitis. Gut 1962; 3: 207
59. Ngo Y, Rambaud JC. 5-Aminosalicylic acid enema (Pentasa) versus hydrocortisone acetate foam (Proctocort) for the treatment of outbreaks of proctitis and cryptogenic proctosigmoiditis. A comparative randomized multicenter trial. Gastroenterol Clin Biol 1992; 16: 558-63
60. Mulder CJJ, Tygat GNJ, Wiltink EHH, et al. Comparison of 5-aminosalicylic acid (3 g) and prednisolone phosphate sodium enemas (30 mg) in the treatment of distal ulcerative colitis. Scand J Gaslroenterol 1988; 23: 1005-8
61. Danish 5-AS A Group. Topical 5-aminosalicylic acid versus prednisolone in ulcerative proctosigmoiditis. Dig Dis Sei 1987; 32: 598-602
62. Campieri M, Gionchetti P, Belluzzi A, et al. Efficacy of 5aminosalicylic acid enemas versus hydrocortisone enemas in ulcerative colitis. Dig Dis Sei 1987; 32: 67S-70S
63. Blanchi Porro G, Ardizzone S, Petrillo M, et al. Low Pentasa dosage versus hydrocortisone in the topical treatment of active ulcerative colitis: a randomized, double-blind study. Am J Gastroenterol 1995; 90: 736-9
64. Halvorsen S, Myren J, Aakvaag A. On the absorption of prednisone and prednisolone disodium phosphate after recta] administration. Scand J Gastroenterol 1969; 4: 582-4
65. Farmer RG, Schumacher OP. Treatment of ulcerative colitis with hydrocortisone enemas: relationship of hydrocortisone absorption, adrenal suppression and clinical response. Dis Colon Rectum 1970; 13: 355-61
66. Friedman G. Tixocortol pivalate (JO 1016). Am J Gastroenterol 1983; 78: 529-30
67. Levinson RA. Intrarectal treatment of ulcerative colitis with tixocortol pivalate, a topical, nonsystemic anti-inflammatory steroid, comparison with hydrocortisone enema [abstract]. Gastroenterology 1986; 90: 1520
68. Hanauer SB, Kirsner JB, Barrett WE. The treatment of leftsided colitis with tixocortol pivalate (TP) [abstract]. Gastroenterology 1986; 90: 1449
69. Mclntrye PB, MacRae FA, Berghouse L, et al. Therapeutic benefits from a poorly absorbed prednisolone enema in distal colitis. Gut 1985; 26: 822-4
70. Hamilton I, Pinder IF, Dickinson RJ, et al. A comparison of prednisolone enemas with low-dose oral prednisolone in the treatment of acute distal ulcerative colitis. Dis Colon Rectum 1984; 27: 701-2
71. Bansky G, Buhler H, Stamm B, et al. Treatment of distal ulcerative colitis with beclomethasone enemas: high therapeutic efficacy without endocrine side effects. Dis Colon Rectum 1987:30:288-92
72. Mulder CJJ, Endert E, van der Heide E. et al. Comparison of beclomethasonediproprionate (2 and 3 mg) and prednisolone sodium phosphate enemas (30 mg) in the treatment of ulcerative proctitis: an adrenocortical approach. Neth J Med 1989; 35: 18-24
73. van der Heide H, van den Brandt-Gradel V, Tytgat GNJ, et al. Comparison of beclomethasone dipropionate and prednisolone 21 -phosphate enemas in the treatment of ulcerative proctitis. J Clin Gastroenterol 1988; 10: 169-72
74. Danielsson A. Hellers G, Lyrenas E. et al. A controlled randomized trial of budesonide versus prednisolone retention enemas in active distal ulcerative colitis. Scand J Gastroenterol 1987: 22: 987-92
75. The Danish Budesonide Study Group. Budesonide enema in distal ulcerative colitis. A randomized dose-response trial with prednisolone enema as positive control. Scand J Gastroenterol 1991:26: 1225-30
76. Danielsson A, Lofberg R, Persson T. et al. A steroid enema, budesonide, lacking systemic effects for the treatment of distal ulcerative colitis or proctitis. Scand J Gastroenterol 1992: 27: 9-12
77. Lofberg R, OstergaardThomsenO, Langholz E, et al. Budesonide versus prednisolone retention enemas in active distal ulcerative colitis. Aliment Pharmacol Ther 1994; 8: 623-9
78. Tarpila S, Turunen U, Seppala K, et al. Budesonide enema in active haemorrhagic proctitis - a controlled trial against hydrocortisone foam enema. Aliment Pharmacol Ther 1994: 8: 591-5
79. Bayless T. Sninsky C, the U.S. Budesonide Enema Study Group. Budesonide enema is an effective alternative to hydrocortisone enema in active distal ulcerative colitis [abstract]. Gastroenterology 1995; 108: A778
80. Harig JM. Soergel KH, Komorowski RA, et al. Treatment of diversion colitis with short-chain fatty acid irrigation. N Ensl J Med 1989:320:23-8
81. Scheppach W, Sommer H, Kirchner T, et al. Effect of butyrate enemas on the colonie mucosa in distal ulcerative colitis. Gastroenterology 1992; 103: 51-6
82. Steinhart AH, Brzezinski A, Baker JP. Treatment of refractory ulcerative proctosigmoiditis with butyrate enemas. Am J Gastroenterol 1994:89: 179-83
83. Vernia P. Cittadini M, Caprilli R, et al. Topical treatment of refractory distal ulcerative colitis with 5-ASA and sodium butyrate. Dig Dis Sei 1995; 40: 305-7
84. Senagore AJ, MacKeigan JM, Scheider M. et al. Short-chain fatty acid enemas: a cost-effective alternative in the treatment of nonspecific proctosigmoiditis. Dis Colon Rectum 1992; 35: 923-7
85. Steinhart AH, Hiruki T, Brzezinski A, et al. Treatment of leftsided ulcerative colitis with butyrate enemas: a randomized controlled trial [abstract]. Gastroenterology 1995; 108: A92I
86. Vernia P, Marcheggiano A. Caprilli R, et al. Short-chain fatty acid topical treatment in distal ulcerative colitis. Aliment Pharmacol Ther 1995; 9: 309-13
87. Brynskov J, Freund L, Thomsen OO, et al. Treatment of refractory ulcerative colitis with cyclosporin enemas [letter]. Lancet 1989; I: 721-2
88. Sandborn WJ, Tremaine WJ. Schroeder KW, et al. Cydosporine enemas for treatment resistant, mildly to moderately aetive. left-sided ulcerative colitis. Am J Gastroenterol 1993: 88: 640-5
89. Sandborn WJ, Tremaine WJ, Schroeder KW, et al. A placebocontrolled trial of cyclosporine enemas for mildly to moderately active left-sided ulcerative colitis. Gastroenterology 1994: 106: 1429-35
90. Heatley RV. Calcraft BJ. Rhodes J, et al. Disodium cromoglycate in the treatment of chronic proctitis. Gut 1975: 16: 559-663
91. Grace RH, Gent AE, Hellier MD. Comparative trial of sodium cromoglycate enemas with prednisolone enemas in the treatment of ulcerative colitis. Gut 1987: 28: 88-92
92. Shea-Donohue T, Steel L. Montcalm E. et al. Gastric protection by sucralfate: role of mucus and prostaglandins. Gastroenterology 1986:91: 660-6
93. Carling L, Kagevi I. Borvall E. Sucralfate enema (SUC) effective in 1BD (letter]? Endoscopy 1986; 18: 115
94. Riley SA, Gupta 1. Mani V. A comparison of sucralfate and prednisolone enemas in the treatment of active distal ulcerative colitis (abstract). Gastroenterology 1988; 94: A377
95. Kochhar R, Mehta SK, Aggarwal R, et al. Sucralfate enema in ulcerative rectosigmoid lesions. Dis Colon Rectum 1990: 33: 49-51
96. Ryder SD. Walker RJ. Jones H. et al. Rectal bismuth subsalicylate as therapy for ulcerative colitis. Aliment Pharmacol Ther 1990; 4: 333-8
97. Pullan RD. Ganesh S. Mani V, et al. Comparison of bismuth citrate and 5-aminosalicylic acid enemas in distal ulcerative colitis: a controlled trial. Gut 1993; 34: 676-9
98. Bjorck S. Dahlstrom A. Ahlman H. Topical treatment of ulcerative proctitis with lidocaine. Scand J Gastroenterol 1989; 24: 1061-72
99. Bjorck S. Dahlstrom A. Johansson L. et al. Treatment of the mucosa with local anaesthetics in ulcerative colitis. Agents Actions 1992; Special Conference Issue: C60-C72
100. Brandt LJ. Bernstein LH, Boley SJ. et al. Metronida/ole therapy for perianal Crohn's disease: a follow-up study. Gastroenterology 1982; 83: 383-7
101. Ursing B, Aim T. Baranay F. A comparative study ot metronidazole and sulfasalazine for active Crohn's disease: the cooperative Crohn's disease study in Sweden. Gastroenterology 1982:83:550-62
102. Davies PS, Rhodes J. Heatley RV, et al. Metronidazole in the treatment of chronic proctitis: a controlled trial. Gut 1977: 18: 680-1
103. Nygaard K. Bergan T, Bjorneklett A. et al. Topical metronidazole treatment in pouchitis. Scand J Gastroenterol 1994; 29: 462-7
104. Kühn R. Lohler J. Rennick D. et al. Interleukin-10-deficient mice develop chronic enlerocolitis. Cell 1993: 75: 263 74
105. Schreiber S, Heinig T, Heinz-Günther T, et al. Immunoregulatory role of interleukin 10 in patients with inflammatory bowel disease. Gastroenterology 1995: 108: 1434-44